Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Overview
This Phase 3 study will evaluate whether \[18F\]Floretyrosine (\[18F\]FET) PET imaging can help distinguish active brain tumor growth from treatment-related changes in patients with brain metastases who have unclear MRI findings after treatment. The study has two parts. Part 1 will identify the lowest effective dose of \[18F\]FET PET that provides reliable imaging results. Part 2 will evaluate the accuracy of \[18F\]FET PET, using the optimized dose, for distinguishing tumor progression from treatment-related changes. Study results will be compared with information from follow-up imaging, clinical assessments, and, when available, tissue samples obtained during routine clinical care. The goal is to determine whether \[18F\]FET PET can improve diagnostic accuracy and support clinical decision-making for patients with brain metastases.
Study contact
Sahar Khan, Clinical Project Manager, MBA, MS
Sapna Shah, Senior Director, Clinical Operations, MD
Eligibility
Patient Education
Patient education not yet provided.
Publications
Publications not yet provided.
Locations
Loading…
Help us improve your experience